In this study, we confirmed that tunicamycin enhanced the antitumor activity of trastuzumab against HER2-overexpressing breast cancer through cell cycle arrest and apoptosis by increasing p21 expression and decreasing the EGFR family signaling pathways. The gene discussed is ERBB2; the disease is breast cancer.